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Abstract
Background: Little information is available on leptin concentrations in individuals with IGT. This
study aims to determine and correlate leptin levels to anthropometric measures of obesity in pre-
diabetic, (IFG and IGT), type 2 diabetic and normoglycaemic Saudis.
Methods: 308 adult Saudis (healthy controls n = 80; pre-diabetes n = 86; Type 2 diabetes n = 142)
participated. Anthropometric parameters were measured and fasting blood samples taken. Serum
insulin was analysed, using a solid phase enzyme amplified sensitivity immunoassay and also leptin
concentrations, using radio-immunoassay. The remaining blood parameters were determined using
standard laboratory procedures.
Results: Leptin levels of diabetic and pre-diabetic men were higher than in normoglycaemic men
(12.4 [3.2–72] vs 3.9 [0.8–20.0] ng/mL, (median [interquartile range], p = 0.0001). In females, leptin
levels were significantly higher in pre-diabetic subjects (14.09 [2.8–44.4] ng/mL) than in
normoglycaemic subjects (10.2 [0.25–34.8] ng/mL) (p = 0.046). After adjustment for BMI and
gender, hip circumference was associated with log leptin (p = 0.006 with R2 = 0.086) among all
subjects.
Conclusion: Leptin is associated with measures of adiposity, hip circumference in particular, in the
non-diabetic state among Saudi subjects. The higher leptin level among diabetics and pre-diabetics
is not related to differences in anthropometric measures of obesity.
Background
Saudi Arabia, a Middle Eastern country with a population
of 22 million, has undergone significant economic and
cultural changes over the past thirty years. Approximately
60% of the population are urbanised and have adopted a
'Westernised' lifestyle in terms of diet and physical activity
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[1]. Obesity and associated components of the metabolic
syndrome have become increasingly common in the
Saudi population, which may partially explain the
increased incidence of coronary heart disease (CHD) [2-
7]. In the USA, 17.1% of overweight adults aged 45–74
years were found to have impaired glucose tolerance
(IGT); 11.9% had impaired fasting glucose (IFG); 22.6%
had prediabetes; and 5.6% had both IGT and IFG [8].
Increased risk of CHD in subjects with IGT is supported by
data from the Honolulu [8], Chicago [9] and Islington
[10] heart studies, which demonstrated that mortality
from CHD increased gradually as glucose tolerance deteri-
orated, with no apparent threshold value. In 1997, the
American Diabetes Association (ADA) defined pre-diabe-
tes as fasting plasma glucose (FPG) 6.1–7.0 mmol/L
(110–126 mg/dl) [11]. The choice of the 6.1 mmol/L
threshold was based partly on the increased risk of devel-
oping both microvascular and macrovascular complica-
tions above this level [11]. However, it has now been
shown that the fasting glycaemia threshold of 6.1 mmol/
L does not create a category of glucose homeostasis equiv-
alent to that of IGT, either for the subsequent develop-
ment of diabetes or CHD [12].
Diabetes increases the risk of developing cardiovascular
disease by 2–3 times and increases by as much as 50% the
risks of non-cardiovascular mortality associated with this
condition [13-15]. This high risk is not completely
explained by the traditional risk factors [16,17]. Pre-dia-
betes is also associated with cardiovascular diseases
(CVD) [18,19], but it is unclear if it is an independent risk
factor, because it commonly co-exists with other cardio-
vascular risk factors present in the metabolic syndrome.
The overall prevalence of type 2 diabetes in Saudi adults is
23.7% [20] while the overall prevalence of CHD is 5.5%
[5]. However, the percentage of Saudi subjects who had an
FPG in the impaired fasting glucose range (6.1–7.0 mmol/
L) was 14.1% [7].
In human beings, serum leptin concentration is directly
proportional to body fat mass, but it is leptin resistance
and not leptin deficiency per se which is regarded as a
pathogenic mechanism in human obesity. Leptin concen-
trations vary widely among individuals with similar fat
mass, indicating other possible factors for its determina-
tion [21,22]. Leptin may be a marker of risk of CHD, at
least in males, and contributes to the CHD risk profile in
subjects with insulin resistance [23]. Not much informa-
tion is available on leptin concentrations in individuals
with IGT and to our knowledge there has been no study of
leptin in pre-diabetics within the region.
This study aims to determine and compare the serum lep-
tin concentrations of diabetic and non-diabetic patients
with those in patients who have pre-diabetes and to corre-
late it with anthropometric measures of obesity.
Methods
Subjects
In the present study, subjects were selected from the roster
of adult, ambulant, non-pregnant patients attending the
Diabetes Center at the King Abdulaziz University Hospital
in Riyadh, Saudi Arabia. Ethical approval was obtained
from the local institution's review committee and consent
was obtained from all participants. For the purposes of
this study, subjects were classified into categories of
abnormal glucose homeostasis if they had a single abnor-
mal FPG. 142 patients had type-2 diabetes (FPG > 7.1
mmol/L) (97 males and 45 females). All patients with dia-
betes were treated with a low-carbohydrate diet, with or
without oral antidiabetetic agents, mainly glibenclamide
and metformin. 86 pre-diabetic subjects (49 males and 37
females) were defined on the basis of modified ADA crite-
ria [24]. Pre-diabetes was diagnosed when the fasting
plasma glucose was between 5.6 mmol/L – 7.0 mmol/L
(100–126 mg/dL). 80 Saudi individuals (45 males and 35
females), with no prior history of CHD or diabetes, were
recruited as controls (no diabetes).
Anthropometric parameters
All subjects underwent a full physical examination and
completed a general questionnaire. Height was measured
to the nearest 0.5 cm and weight to the nearest 0.1 kg.
Waist circumference (cm) was measured at the horizontal
circumference midway between the lowest rib margin and
the iliac crest and the hip circumference (cm) was meas-
ured at the maximum circumference over the buttocks.
Body mass index (BMI) was calculated as weight (kg)
divided by height (m) squared. Groups were matched for
BMI.
Laboratory methods
Blood samples were collected after a 12-hour fast for the
determination of glucose, insulin, total cholesterol, HDL,
triglycerides, apolipoprotein A1 (apo A1), apolipoprotein
A2 (apo A2) and leptin. All samples were stored at -70°C
prior to analysis by using routine laboratory methods,
except for insulin and leptin assay. Insulin was analyzed
by a solid phase enzyme amplified sensitivity immu-
noassay (Medgenix INS-ELISA, Biosource, Belgium). Lep-
tin concentrations were measured by radio-immunoassay
(Linco Research, St. Charles, MO). Homeostasis model
assessment-insulin resistance (HOMA-IR) and β-cell func-
tion index were derived using the HOMA equation [25].
Statistical Analysis
Data were analysed using the Statistical Package for the
Social Sciences (SPSS) version 10 (SPSS, Evanston, IL,
USA) for Windows. Biochemical parameters not normallyCardiovascular Diabetology 2007, 6:18 http://www.cardiab.com/content/6/1/18
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distributed were analyzed after being logarithmically
transformed. Students' unpaired t-test and one-way anal-
ysis of variance (ANOVA) were used to compare the
results of the different groups. Simple and partial correla-
tion coefficients between the variables were determined
and multiple regression analysis was performed to deter-
mine the relationships between the variables of interest.
Data were expressed as mean (SD) or median (range); sta-
tistical significance was set at p < 0.05.
Results
Table 1 presents the clinical and metabolic characteristics
of the male subjects. It is evident that those in the diabetes
group were significantly older (p < 0.0001), with higher
fasting glucose and leptin levels (p < 0.0001, 0.012 respec-
tively) than those in the pre-diabetes and control groups.
At the same time, the pre-diabetes group had significantly
elevated systolic blood pressure (p = 0.046) and fasting
glucose levels (p < 0.0001), compared to the controls.
Table 2 highlights the clinical and metabolic parameters
in the females. In the diabetes and pre-diabetes group,
FPG and LDL were significantly higher than in the control.
Total cholesterol was also significantly higher in women
with diabetes (p = 0.03).
Serum leptin was significantly higher in the men with dia-
betes than in their non-diabetic counterparts (12.4 [3.2–
72]; p = 0.0001). In the female patients, serum leptin was
higher in those with pre-diabetes (14.09 [2.8–44.4]) than
in the controls.
Stepwise linear regression analysis revealed a positive cor-
relation between log leptin and hip circumference and
BMI (R = 0.31, p = 0.002; R = 0.26, p = 0.006 respectively).
Even after adjustment for BMI, there was a positive associ-
ation between log leptin and hip circumference with an R2
= 0.086 and p value of 0.006 (see Figure 1). The rest of the
findings were non-contributory.
Discussion
Insulin resistance is the common factor in a range of risk
factors for atherosclerosis, specifically hypertension, dysl-
ipidemia and abnormal glucose metabolism. As has been
shown in other populations [26-29], the pre-diabetic
males had a significantly higher systolic blood pressure
and fasting plasma glucose than the control subjects had.
Many [30,31], but not all studies [32,33] of the general
population have shown a positive association of indices
of insulin resistance with arterial wall changes, CHD and
CVD. The clustering of risk factors increases the risk of
atherosclerosis [34-36].
Data were presented according to gender, since it is
already an established fact that leptin levels are signifi-
cantly higher in women than in men. There are several
possible explanations for the difference. One is that
females have more adipose tissue than males, but a grow-
ing literature indicates that estrogen, especially at higher
levels, will stimulate the production of leptin, whereas
androgens will suppress the levels of leptin [37]. In this
cross-sectional study, we found positive correlations
between leptin and hip circumference in pre-diabetic
patients. This is consistent with a previous study, which
also showed that this group is at high risk of developing
Table 1: Clinical characteristics and metabolic parameters of male subjects with type-2 diabetes, pre-diabetes and no diabetes
No Diabetes Pre-diabetes Type-2 Diabetes
N4 5 4 9 9 7
Age (years) 45.7(12.6) 50.1(11.6) 54.5(10.7)f
Systolic blood pressure (mm Hg) 123.1(16.9) 132.8(25.1)a 130.7(17.5)
Diastolic blood pressure (mm Hg) 79.9(9.1) 85.1(11.4) 82.9(10.5)
BMI (Kg/m2) 29.2(7.3) 28.5(4.3) 27.3(4.1)
Waist (cm) 93.7(18.2) 98.6(10.1) 96.4(15.1)
Hips (cm) 95.9(15.7) 100.5(13.9) 99.8(14.4)
Fasting Glucose (mmol/L) 4.8(0.6) 6.1(0.4)f 13.7(5.0)f
Cholesterol (mmol/L) 5.2(1.6) 5.6(1.4) 6.5(1.9)f
HDL (mmol/L) 0.94(0.3) 1.2(0.4) 0.9(0.4)
Triglyceride (mmol/L) 1.8(0.6–6.7) 1.9(0.7–6.3) 2.5(1.6–15)
LDL (mmol/L) 3.3(1.1) 3.9(1.6) 4.2(1.8)b
Insulin μmol/L * 12.6(2–99) 12.3 (2–36) 16.2(2–70)
Leptin ng/mL * 3.9(0.8–20) 7.6(1.2–72)d 12.4(3.2–72)c
APO A1 mg/dL 0.9(0.3) 0.9(0.5) 0.9(0.3)
APO A2 mg/dL 0.4(0.1) 0.4(0.1) 0.3(0.1)
HOMA-IR * 3.3(0.3–23.8) 3.5(0.5–10.2) 9.6(1.1–49.7)e
Data are presented as means (SD) or as medians (interquartile range) for insulin, leptin and HOMA-IR data. The P-values shown are comparisons of 
metabolic characteristics for case control versus either prediabetic patients or those with T2DM: a) 0.046; b) p = 0.03; c) p = 0.012; d) p = 0.004; 
e) p = 0.001; f) p < 0.0001.Cardiovascular Diabetology 2007, 6:18 http://www.cardiab.com/content/6/1/18
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CHD [38]. The positive association with hip circumfer-
ence remained significant after adjusting for gender and
BMI, which confirmed the results in previous studies for
healthy men and women [39,40]. With impaired glucose
tolerance, small changes in circulating insulin also alter
insulin levels [41].
Serum leptin concentration may contribute to the risk of
CVD by altering lipid metabolism and contributing to
hypertension via the activation of the sympathetic nerv-
ous system and increasing renal sodium re-absorption
[42,43]. However, in our study there was no correlation
between leptin and blood pressure. In another study, lep-
tin signaling directly promoted atherosclerosis and may
therefore represent a therapeutic target for the prevention
of atherosclerosis [44]. Lichnovska and her colleagues in
their recent report mentioned the significant role of serum
leptin in the progression of insulin resistance, but this was
not confirmed in the present study [45]. The difference
can be due to the fact that the earlier study considered eld-
erly and hyperlipemic patients, while the present study
focused on pre-diabetic, diabetic and non-diabetic adults.
Our results, however, confirm the results of Adamia et al.,
which reveal no correlation between leptin and insulin
resistance [46].
A family history of diabetes was found to have a negative
association with leptin in pre-diabetic patients; this con-
firms a previous study which reported that healthy lean
non-diabetic Asian Indians are more insulin resistant than
other ethnic groups, despite similarities in their living
environment [47]. Waist circumference has been postu-
lated to have closer associations with the biomarkers of
CHD than BMI has [48]. The association of leptin to waist
circumference (a surrogate for upper body obesity) and
hip circumference confirms findings in Mexican American
populations [49,50]. After adjustment for BMI, serum lep-
tin concentrations in pre-diabetic men were independent
of waist circumference, but in women they were associ-
ated with hip circumference. Hip circumference is a proxy
measure of peripheral fat in serum leptin concentrations,
aside from the fact that women have a significantly larger
volume of subcutaneous fat than do men. In the control
subjects, leptin concentrations were directly and signifi-
cantly related to subcutaneous fat, with a strong inverse
relationship to waist-hip ratio. When the results were con-
sidered according to gender, it was found that 33.1% of
the male Saudis with waist circumference >102 cm, had
diabetes. In female subjects, 27% of those with a high
waist circumference ≥88 cm had diabetes, compared to
only 13.4% of those with a normal waist circumference
[20]. Leptin is related to waist and hip circumference and
is directly proportional to body fat. However, in those
with diabetes, this relationship is lost, reflecting the effect
of other factors, including hyperinsulinaemia and the acti-
vation of sub-clinical inflammation.
Conclusion
The significant correlation of leptin to selected anthropo-
metric measurements of obesity is confirmed in non-dia-
betic Saudi Subjects. In those with diabetes, this
relationship is lost, reflecting the effect of other factors,
including hyperinsulinaemia and the activation of sub-
clinical inflammation.
Table 2: Clinical characteristics and metabolic parameters of female subjects with type-2 diabetes, pre-diabetes and healthy control 
subjects
No diabetes Pre-diabetes Type-2 diabetes
N3 5 3 7 4 5
Age (years) 43.6(11.3) 43.3(11.7) 49.0(12.6)d
Systolic blood pressure (mm Hg) 122.8(23.1) 127.3(24.2) 123.6(18.6)
Diastolic blood pressure (mm Hg) 79.4(16.5) 79.8(8.03) 80.7(10.3)
BMI (kg/m2) 30.4(6.4) 32.5(8.4) 32.5(10.3)
Waist (cm) 90.5(12.5) 91.8(13.5) 96.2(17.9)
Hips (cm) 105.3(14.1) 104.8(17.9) 106.7(20.8)
Fasting Glucose (mmol/L) 4.8(0.9) 6.1(0.4)b 14.1(5.5)b
Cholesterol (mmol/L) 5.2(1.3) 5.3(1.1) 6.6(1.9)b
HDL (mmol/L) 1.1(0.4) 0.9(0.4) 1.1(0.3)
Triglyceride (mmol/L) 1.9(1.9) 1.6(0.9) 2.6(1.4)
LDL (mmol/L) 3.5(1.4) 3.6(1.1)d 4.4(1.5)c
Insulin (μmol/L)* 15.2(2–62) 13.5(6–26) 14.04(1–52)
Leptin ng/mL * 10.2(0.25–34.8) 14.09(2.8–44.4)a 13.3(3.6–49.1)
APO A1 mg/dL 0.8(0.4) 0.9(0.4) 1.2(2.5)
APO A11 mg/dL 0.4(0.1) 0.4(0.1) 0.4(0.2)
HOMA IR * 3.1(0.3–12.5) 3.6(1.5–7.3) 7.8(0.6–28.4)b
*Data are presented as means (SD) or as medians (interquartile range) for insulin, leptin and HOMA-IR data. The P-values shown are comparisons 
of metabolic characteristics for case control versus either prediabetics or patients with T2DM: a) 0.046; b) p = 0.03; c) p = 0.004; d) p < 0.001Cardiovascular Diabetology 2007, 6:18 http://www.cardiab.com/content/6/1/18
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